-       Report 
   - April 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  375 Pages 
    Global
   
   From       €4494EUR$5,000USD£3,941GBP 
                 -       Report 
   - November 2025
    -  378 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  470 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  564 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - November 2025
    -  192 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Report 
   - August 2025
    -  182 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  194 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - April 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - November 2025
    -  193 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                  -       Clinical Trials 
   - April 2025
    -  100 Pages 
    Global
   
   From       €2157EUR$2,400USD£1,892GBP 
      €2696EUR$3,000USD£2,365GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1438EUR$1,600USD£1,261GBP 
      €1798EUR$2,000USD£1,577GBP 
                  -       Clinical Trials 
   - April 2025
    -  240 Pages 
    Global
   
   From       €1798EUR$2,000USD£1,577GBP 
      €2247EUR$2,500USD£1,971GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €899EUR$1,000USD£788GBP 
      €1124EUR$1,250USD£985GBP 
             
          The Psoriasis Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat psoriasis, a chronic skin condition. Psoriasis is characterized by red, scaly patches on the skin, and can cause itching, burning, and pain. Psoriasis drugs are designed to reduce inflammation, reduce the rate of skin cell growth, and reduce the severity of symptoms.
The Psoriasis Drugs market is highly competitive, with many companies offering a variety of    treatments. Some of the major players in the market include AbbVie, Amgen, Celgene, Janssen, and Novartis. These companies offer a range of treatments, including topical creams, oral medications, and biologic drugs. Other companies in the market include Sun Pharmaceuticals, Glenmark Pharmaceuticals, and Lupin Pharmaceuticals. Show Less   Read more